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 JCS Advance Online Article. Posted on 3 January 2017
 Abbreviations: DOX: Doxycycline; ETC: Electron transport chain; IPA: Ingenuity 
Pathway Analysis; iTRAQ: isobaric Tag for Relative and Absolute Quantitation; NMJ: 
Neuromuscular junction; OCR: Oxygen consumption rates; OD: Optical density; PD: 
Parkinson’s disease; sfxn3: Sideroflexin 3. 
 
Summary Statement 
Comparative proteomics revealed that mitochondrial proteins are a major target for α-
synuclein. Sideroflexin 3 (sfxn3) was identified as one α-synuclein-dependent 
mitochondrial protein capable of altering synaptic morphology in vivo. 
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 Abstract 
α-synuclein plays a central role in Parkinson’s disease, where it contributes to the 
vulnerability of synapses to degeneration. However, the downstream mechanisms 
through which α-synuclein controls synaptic stability and degeneration are not fully 
understood. Here, comparative proteomics on synapses isolated from α-synuclein-/- 
mouse brain identified mitochondrial proteins as primary targets of α-synuclein, 
revealing 37 mitochondrial proteins not previously linked to α-synuclein or 
neurodegeneration pathways. Of these, sideroflexin 3 (sfxn3) was found to be a 
mitochondrial protein localized to the inner mitochondrial membrane. Loss of sfxn3 did 
not disturb mitochondrial electron transport chain function in mouse synapses, 
suggesting that its function in mitochondria is likely independent of canonical 
bioenergetic pathways. In contrast, experimental manipulation of sfxn3 levels disrupted 
synaptic morphology at the Drosophila neuromuscular junction. These results provide 
novel insights into α-synuclein-dependent pathways, highlighting an important 
influence on mitochondrial proteins at the synapse, including sfxn3. We also identify 
sfxn3 as a novel mitochondrial protein capable of regulating synaptic morphology in 
vivo.  
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 Introduction  
α-synuclein is an abundant neuronal protein with a central role in the pathophysiology 
of Parkinson’s disease (PD). Abnormal accumulation of protein aggregates containing 
α-synuclein in Lewy bodies is a pathological hallmark of PD, and mutations and 
multiplications of SNCA, the gene encoding α-synuclein, have been linked with familial 
cases of the disease (Stefanis, 2012). The physiological and neurotoxic functions of α-
synuclein have been associated with a variety of cellular processes, including 
neurotransmission, protein degradation and mitochondrial function (Lashuel et al., 
2013; Stefanis, 2012). For example, α-synuclein has previously been shown to affect 
mitochondrial functions including complex I activity, oxidative stress and protein 
import pathways (Di Maio et al., 2016; Liu et al., 2009; Parihar et al., 2008). 
 
At the level of the synapse, α-synuclein supports neurotransmission by promoting 
SNARE-complex assembly and regulating synaptic vesicle recycling and mobility 
(Burre et al., 2014; Murphy et al., 2000; Scott and Roy, 2012). However, whereas 
increased levels of α-synuclein attenuate the neurodegenerative phenotype caused by 
deletion of CSP- (Chandra et al., 2005), both increased expression and deletion of α-
synuclein impair synaptic functions (Burre et al., 2010; Cabin et al., 2002; Nemani et 
al., 2010). Therefore, the molecular mechanisms through which α-synuclein influences 
synaptic form and function remain unclear.  
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 Results and Discussion 
Identification of novel α-synuclein targets at the synapse 
To uncover molecular mechanisms downstream of α-synuclein relevant for synaptic 
form and function, we quantified changes in the synaptic proteome of mice lacking α-
synuclein (Fig. 1A). iTRAQ proteomics on synaptosomes from α-syn+/+ and α-syn-/- 
mice identified 2,615 individual proteins. Raw mass spectrometry data was filtered to 
leave only those proteins identified by at least two unique peptides and with expression 
levels consistently altered by 15% across two independent technical replicates (Table 
S1). The remaining 200 proteins were submitted to bioinformatics pathway analysis 
using IPA, DAVID and VarElect, revealing a striking enrichment of proteins (74 out of 
200) belonging to mitochondrial pathways. This provides significant experimental 
support for the hypothesis that α-synuclein has important physical and/or functional 
interactions with mitochondria (Haelterman et al., 2014; Nakamura, 2013). Further 
bioinformatics analysis identified 37 mitochondrial proteins not previously associated 
with α-synuclein or neurodegeneration (Fig. S1).  
 
To select individual proteins from the short-list of 37 to be prioritised for further 
analyses, we performed extensive literature searches to identify those with potential 
links to PD and/or neurodegeneration. Using this approach, Sideroflexin 3 (sfxn3) was 
identified as a protein of particular interest. Studies have reported that levels of sfxn3 
transcripts or protein were deregulated in the substantia nigra of PD patients and in 
rodents subjected to a 6-hydroxydopamine lesion (Charbonnier-Beaupel et al., 2015; 
Fuller et al., 2014; Simunovic et al., 2009). Sfxn1, a protein from the same family, 
interacts with connexin 32, mutations in which cause a Charcot-Marie-Tooth disease 
(Bergoffen et al., 1993; Fowler et al., 2013), and reduced levels of sfxn1 protein have 
been reported in Alzheimer’s disease (Minjarez et al., 2016). In addition, sfxn2 is 
upregulated in a dopaminergic cell line in response to rotenone treatment (Jin et al., 
2007). Sfxn3 belongs to a family of proteins (sideroflexins 1-5) that are putative iron 
transporters, with predicted transmembrane domains and mitochondrial localization 
(Fleming et al., 2001; Li et al., 2010). The functional role of these proteins, however, 
remains poorly understood.  
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 Levels of sfxn3 protein were increased in synapses from α-syn-/- mice (Fig. 1B), 
suggesting that sfxn3 expression is inversely correlated with α-synuclein. To confirm 
this, we over-expressed wild-type α-synuclein in stably transfected SH-SY5Y cells. 
Exposure of SH-SY5Y cells to Doxycycline (DOX) for 24h led to a robust increase in 
α-synuclein (5.78±0.81; n≥9; p=1.7x10-6 in t-test), accompanied by a significant 
decrease in levels of sfxn3 protein (Fig. 1C). Thus, sfxn3 levels are bi-directionally 
regulated by α-synuclein.  
 
It is not clear how α-synuclein regulates levels of sfxn3. One possibility is that α-
synuclein interferes with the import of sfxn3 into mitochondria, since α-synuclein has 
been shown to inhibit the import of nuclear encoded mitochondrial proteins through an 
interaction with TOM20 (Di Maio et al., 2016). In support of this, we found several 
mitochondrial import proteins, such as TIM10B, TIM16 and TOM40, to be upregulated 
in α-syn-/- mice compared to controls (Table S1). 
 
Sfxn3 is a mitochondrial protein enriched in the inner mitochondrial membrane 
Sfxn3 is predicted to be a mitochondrial protein (Pagliarini et al., 2008), but 
experimental evidence confirming its tissue expression and subcellular localisation is 
lacking. We used western blotting to analyse expression levels of sfxn3 protein in mice 
(Fig. 1D). Sfxn3 was highly enriched in brain, both in synaptic and non-synaptic 
fractions, spinal cord and peripheral nerve. It was also present in liver and kidney, but 
was not detectable in skeletal or cardiac muscle. 
 
Isolation of mitochondrial and cytosolic fractions from mouse brain confirmed that 
sfxn3 was expressed exclusively in mitochondria (Fig. 1E). Furthermore, differential 
extraction of mitochondrial outer membrane and mitoplasts of mitochondria from SH-
SY5Y cells revealed that sfxn3 was localised to the mitoplast fraction (Fig. 1F). Given 
the presence of transmembrane domains in the sfxn3 protein (Li et al., 2010), we 
conclude that sfxn3 is preferentially localised to the inner mitochondrial membrane. 
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 Loss of sfxn3 does not influence mitochondrial bioenergetics 
The localisation of sfxn3 to the inner mitochondrial membrane prompted us to ask 
whether sfxn3 plays a role in canonical bioenergetic pathways, including oxidative 
phosphorylation. We isolated purified synaptosomes from WT and sfxn3-KO mice and 
performed mitochondrial respiration assays using a Seahorse XF
e
24 Analyzer. Oxygen 
consumption rates (OCR) during basal respiration were similar between WT and sfxn3-
KO mice (Fig. 2A). Accordingly, the fraction of ATP-linked respiration was 
comparable in WT and sfxn3-KO mice (Fig. 2B). Uncoupling of mitochondria using 
FCCP induced equivalent spare and maximum respiratory OCR rates in WT and sfxn3-
KO synaptosomes, indicating that synaptic mitochondria from sfxn3-KO mice are 
comparable to those from controls with respect to their ability to cope with short periods 
of high energetic demand (Fig. 2A,B). Thus, sfxn3 is not absolutely required for 
mitochondrial bioenergetics pathways, as mitochondrial respiration was unaffected by 
the absence of sfxn3. 
 
To confirm that subtle effects on mitochondrial respiration prompted by reduced levels 
of sfxn3 were not being masked by compensatory mechanisms in enzymatic activity or 
abundance of other key electron transport chain (ETC) proteins, we performed 
enzymatic assays on immunocaptured Complex I and Complex IV (Fig. 2C,E). The 
rates of NADH and cytochrome c oxidation revealed identical enzymatic activities of 
Complex I and Complex IV, respectively, in WT and sfxn3-KO mice (Fig. 2D,F). 
Quantitative western blotting for ATP5A (a component of ATP synthase), and the 
Complex I and IV proteins NDUFB8 and cox IV confirmed that no compensatory 
changes were occurring in these ETC proteins in sfxn3-KO mice (Fig. 2G,H). 
 
Sfxn3 influences synaptic morphology at the Drosophila neuromuscular junction 
(NMJ) 
Given that sfxn3 was identified as a α-synuclein target in synaptic mitochondria, we 
wanted to establish whether sfxn3 contributes to pathways regulating synaptic stability. 
We obtained and mapped a UAS driven P{EPgy2} Drosophila strain demonstrating 
insertion of the promoter in the correct direction and in the 5’UTR of our gene of 
interest, suggesting significant potential for overexpression of sfxn3. The Drosophila 
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 UAS/Gal4 system generated tissue-specific over-expression of sfxn3 in third instar 
larval neurons using the pan-neuronal driver elav-Gal4. High-dose overexpression of 
sfxn3 (TgOE++) led to a significant reduction in the number of synaptic boutons, 
accompanied by an overall increase in mean bouton diameter, at muscle 6/7 and muscle 
12 NMJs (Fig. 3). The most striking phenotype was a reduction in type II boutons 
innervating muscle 12. To confirm that these changes were occurring as a direct result 
of changes in sfxn3 levels, we repeated our analyses with a low dose overexpression of 
sfxn3 (TgOE+). These experiments confirmed no alterations in any of the 
neuromuscular parameters analysed (Fig. 3). Furthermore, analysis of eye morphology 
in TgOE++ flies showed no overt phenotype (Figure 3I). The Drosophila eye is a robust 
and sensitive read-out for identifying neurodegeneration (Sanhueza et al., 2015), 
suggesting that over-expression of sfxn3 selectively influences synaptic morphology 
without initiating neurodegenerative cascades. 
 
Taken together, our results demonstrate an important role for α-synuclein in regulating 
mitochondrial proteins at the synapse. We identify sfxn3 as one mitochondrial protein 
whose levels are bi-directionally regulated by α-synuclein, that is also capable of 
directly influencing synapses in vivo. Further studies will now be required to determine 
the extent to which sfxn3 acts as a key intermediary of α-synuclein-dependent synaptic 
pathology occurring in Parkinson’s disease. Considering that -synuclein itself is 
difficult to target from a therapeutic perspective (as a result of being intrinsically 
disordered, with diverse and poorly understood oligomeric states), targeting sfxn3 may 
ultimately represent an alternative strategy for maintaining synapses in PD. 
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 Materials and methods 
Reagents 
All chemicals were purchased from Sigma Aldrich, except: tissue culture reagents, BCA 
assay, RIPA buffer and Halt Protease Inhibitor Cocktail (Thermo Scientific); Percoll 
(GE Healthcare Biosciences). Buffer compositions are in Table S2. 
 
Mice 
C57Bl/6J (α-syn+/+) and C57Bl/6JOlaHsd (α-syn-/-) mice, carrying a natural α-synuclein 
deletion (Specht and Schoepfer, 2001), were obtained from University of Edinburgh 
breeding stocks. Sfxn3
tm1b(KOMP)Wtsi
 mice (sfxn3-KO mice; 
http://www.mousephenotype.org/data/genes/MGI:2137679) were obtained from the 
Wellcome Trust Sanger Institute Mouse Genetics Project as part of the nPad MRC 
Mouse Consotrium, maintained on a C57Bl/6N background. Mice were of mixed 
gender and 2-4 months old. All work was covered by appropriate UK Home Office 
licenses. 
 
Drosophila 
Drosophila melanogaster were raised on standard cornmeal food at room temperature. 
elav-Gal4 and GMR-Gal4 driver strains were used with stocks obtained from 
Bloomington Drosophila stock center (IDs: y
1
 w
67c23
; P{EPgy2}CG6812
EY02703
; 
Canton-S). Crosses were maintained at 22C for 24 hours before removal of adults and 
embryos were incubated in a water bath to increase levels and activity of Gal4 proteins. 
Incubation temperatures were 25 or 30C for low dose (TgOE+) or high dose 
(TgOE++), respectively. For immunohistochemistry methods see (Sanhueza et al., 
2015). Images were analysed using IMARIS software to determine the number and 
transverse diameter of synaptic boutons. The investigator was blinded to the group 
allocation throughout.  
 
Isolation of synaptosomes for iTRAQ proteomics 
Isolation of crude synaptosomes from α-syn+/+ and α-syn-/- mice was performed as 
described (McGorum et al., 2015; Wishart et al., 2012). Samples were homogenized in 
iTRAQ buffer and supernatant extracts from 4 mice per genotype pooled. 100 μg 
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 protein was labeled with tags (114 and 116 α-syn+/+; 115 and 117 α-syn-/-) before 
injection into an Ultimate RSLC nano UHPLC system coupled to a LTQ Orbitrap Velos 
Pro (Thermo Scientific). Results were filtered to include proteins identified by at least 2 
unique peptides with a ≥15% difference in levels across both α-syn+/+ vs α-syn-/- 
comparisons.  
 
Data were examined using bioinformatics tools: Ingenuity Pathway Analysis (IPA; 
Ingenuity Systems, USA); Database for Annotation, Visualization and Integrated 
Discovery (DAVID; NIH, USA); and VarElect (LifeMap Sciences, USA). IPA was 
used to determine affected molecular pathways (Top Canonical Pathways). DAVID 
Functional Annotation was used to identify enrichment for gene ontology (GO) terms. 
VarElect was used to identify the fraction of data that included proteins associated with 
the terms “mitochondria” and the group of terms “Parkinson’s”, “Parkinson”, “PD”, 
“synuclein” and “SNCA”. 
 
Tissue Culture 
SH-SY5Y cells were electroporated with a Tet-One
TM
 plasmid (Clontech) encoding 
full-length human α-synuclein and a DOX-responsive clonal line was selected and 
maintained in DMEM supplemented with 10% FBS, 1% Penicillin/Streptomycin, 1 mM 
Sodium Pyruvate and 2 µg/mL puromycin. For induction of α-synuclein expression, 24h 
after plating cells were differentiated for 5 days in the presence of 10 µM retinoic acid 
and incubated in DMEM media supplemented with 10 µg/mL of Doxycycline for 24h. 
 
Isolation and fractionation of mitochondria 
Mitochondria were isolated from mouse brain using the Mitochondria Isolation Kit for 
Tissue (Abcam). Fractionation of mitochondria from undifferentiated SH-SY5Y cells 
was performed as described (Nishimura et al., 2014).  
 
Western Blotting 
Western Blotting was performed as described (Eaton et al., 2013), using antibodies in 
Table S3. 
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 Mitochondrial respiration assays 
Mitochondrial respiration assays were performed on purified synaptosomes, isolated 
from mouse forebrain using discontinuous Percoll gradients prepared in Isolation 
Media, as previously described (Choi et al., 2009). 
 
Synaptosomes (10 μg protein/well, ≥5 technical replicas per sample) were loaded into 
wells of XF
e
24 V7 (Seahorse Biosciences) uncoated plates. The plate was centrifuged at 
2.000g, 20 min at 4°C, and 500 μL of Incubation Media were added to each well prior 
to entry into the XF
e
24 Seahorse Analyzer (Seahorse Biosciences). Oxygen 
consumption rates (OCR) were measured in groups of 2 cycles of 1 min wait, 1 min 
mix, 3 min measurements, with an injection between each 2 cycles. Each well was 
sequentially exposed to 4 μg/mL oligomycin (Oligo) to stop ATPsynthase activity, 4 
μM FCCP (FCCP) to dissipate mitochondrial membrane potential and potentiate 
maximum oxidative phosphorylation activity, and 4 μg/mL antimycin A (AA) to inhibit 
complex IV and completely stop mitochondria oxidative phosphorylation. OCR values 
for each injection step were calculated as the mean of the measurements of 2 cycles per 
injection step and used to determine the following parameters: Basal respiration: basal 
mitochondrial respiration before addition of any compound; ATP-linked respiration: 
Basal–Oligo, respiration rates associated with the production of ATP by the 
ATPsynthase; Maximum capacity: FCCP–AA, maximum respiratory capacity achieved 
by the activity of complex I-IV; Spare capacity: FCCP–Basal, mitochondria capacity 
above basal levels that can be recruited in situations of high energetic demand.  
 
Enzymatic Assays 
Enzymatic assays were performed using the Complex I and IV Enzyme Activity 
Microplate Assay kits (Abcam) according to manufacturer’s instructions. 
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 Statistical analysis 
Quantitative data was collected using Microsoft Excel®. Statistics for pathway analysis 
and gene ontology enrichments were calculated by their respective software, using the 
right-tailed Fisher’s Exact test. All other statistics were performed using GraphPad 
Prism® (detailed in the results section or figure legends). Statistical significance was 
considered p<0.05. 
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 Figures 
 
 
 
 
Figure 1: Loss of α-synuclein at the synapse leads to widespread disruption of 
mitochondrial proteins, including sfxn3 
A) Schematic overview of experimental design. B) Sfxn3 protein levels were 
significantly upregulated in synaptosomes from -syn-/- compared to -syn+/+ controls. 
****p<0.0001, unpaired t-test. Cox IV; loading control. C) Sfxn3 protein levels were 
significantly reduced in SH-SY5Y cells overexpressing WT α-synuclein induced by 
Doxycycline (+DOX). ***p<0.001, unpaired t-test. Actin; loading control. D) 
Representative western blot showing sfxn3 expression across several tissues from an 
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 adult wild-type mouse. Cox IV was used as a mitochondrial marker. E) Sfxn3 was 
exclusively localised to mitochondrial, but not cytosolic, fractions isolated from mouse 
brain. Cox IV was used as a mitochondrial marker and GAPDH as a cytosolic marker. 
F) Sfxn3 was exclusively localised to the inner mitochondrial membrane. Outer 
mitochondrial membrane (OMM) and mitoplasts (Mit.) were isolated from 
undifferentiated SH-SY5Y cells. VDAC2 was used as a marker for the OMM and 
ATP5A as a marker for the mitochondrial fraction. All data are mean±s.e.m. 
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Figure 2: Loss of sfxn3 does not affect mitochondrial bioenergetics  
A) Identical oxygen consumption rates (OCR) in synaptosomes from WT and sfxn3-KO 
mice. Dashed vertical lines indicate the time of injection of Oligomycin (Oligo), FCCP 
(FCCP) and Antimycin A (AA). n=3. B) Bioenergetic parameters derived from A (see 
methods). n=3, p>0.05 unpaired t-test. C) Complex I activity measured by tracking 
absorbance of oxidised NADH. n=3. D) Rate of Complex I activity derived from C 
shows the enzymatic activity of Complex I is not compromised in sfxn3-KO mice. n=3, 
p>0.05 unpaired t-test. E) Complex IV activity measured by tracking absorbance of 
reduced cytochrome c. n=3. F) Rate of Complex IV activity derived from E shows the 
oxidation of cytochrome c is not affected in sfxn3-KO mice. n=3, p>0.05 unpaired t-
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 test. G, H) Western blotting showing unaltered levels of key ETC proteins in 
synaptosomes from sfxn3-KO mice. n=3, p>0.05 unpaired t-test. All data are 
mean±s.e.m. 
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Figure 3: Sfxn3 regulates synaptic morphology at the neuromuscular junction in 
Drosophila.  
A, B) NMJs on muscles 6/7 (A) and 12 (B) of control and transgenic larvae, with low 
(TgOE+) and high (TgOE++ ) overexpression of sfxn3. Note the reduction in boutons in 
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 TgOE++ NMJs (Grey: anti-HRP; Yellow: pseudo-coloured synaptic boutons). Scale = 
10 μm. C-H) Reduction in the number of boutons and increase in mean bouton diameter 
on NMJs from muscles 6/7 (C,D) and 12 (F,G) overexpressing sfxn3 (TgOE++). 
mean±s.e.m., **p<0.01, ***p<0.001 One-Way ANOVA with Tukey post-test. 
Distribution of bouton diameter from NMJs on muscles 6/7 (E) and 12 (H) showing a 
specific reduction of small size (<1.5 μm) boutons in TgOE++ larvae. I) Representative 
images eyes from control and TgOE++ flies demonstrating no overt phenotype.  
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 Table 1. Pathway and Gene Ontology analyses reveal an enrichment of 
mitochondrial proteins with modified levels in synapses lacking α-synuclein 
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Supplementary Information for Amorim et al. 
Table S1. Proteomics filtered data-set. 
UniProt Description Ratio Mitochondria 
Evidence 
Novel 
Q9DB15 39S ribosomal protein L12, mitochondrial 1.17 Y Y 
P63038 60 kDa heat shock protein, mitochondrial  1.16 Y N 
Q3TQP7 Acetyl-CoA Acetyltransferase 1 1.17 Y Y 
Q14BV7 Acyl-Coenzyme A binding domain containing 6  0.74 N N / A 
Q546G4 Albumin 1 (Precursor)  1.17 Y N 
Q9CZS1 Aldehyde dehydrogenase X, mitochondrial  1.22 Y Y 
Q3UJW9 Aldo-Keto Reductase Family 1, Member A1 (Aldehyde Reductase) 1.16 Y N 
B2RUJ5 Amyloid beta A4 precursor protein-binding family A member 1  0.74 N N / A 
B1AV14 Apolipoprotein, MICOS complex subunit Mic27 1.16 Y Y 
Q53YU5 Apoptosis repressor interacting with CARD  0.83 Y Y 
Q5SUV9 Aromatic-L-amino-acid decarboxylase (Fragment)  1.26 N N / A 
Q3TGE1 ARP3 Actin-Related Protein 3 Homolog 0.71 N N / A 
Q9DB20 ATP synthase subunit  1.32 Y N 
Q06185 ATP synthase subunit e, mitochondrial  0.73 Y Y 
Q8CF81 ATP-dependent Clp protease proteolytic subunit  1.19 Y Y 
A2AUK5 Band 4.1-like protein 1  0.78 N N / A 
A2AHX9 Bcl-2-like protein 1 (Fragment)  0.63 Y N 
Q91ZZ3 Beta-synuclein 1.44 Y N 
Q3U6G1 Biliverdin reductase B (Flavin reductase (NADPH))  1.18 N N / A 
P61022 Calcineurin B homologous protein 1  0.76 N N / A 
P62204 Calmodulin  0.74 N N / A 
G3UXG7 Casein kinase II subunit beta 1.23 N N / A 
Q9JM96 Cdc42 effector protein 4 1.18 N N / A 
B1AUQ7 Centrin-2 (Fragment) 0.69 N N / A 
Q9CQ10 Charged multivesicular body protein 3 0.73 N N / A 
Q9D8B3 Charged multivesicular body protein 4b 0.77 N N / A 
Q3TJ95 Clathrin, Light Chain B 1.25 N N / A 
Q921J6 Cldn10 protein (Fragment)  0.82 N N / A 
O89079 Coatomer subunit epsilon  0.77 N N / A 
Q544Y7 Cofilin 1, non-muscle  1.16 Y N 
Q3UHW9 Cofilin 2 1.22 N N / A 
Q5SNY8 Coiled-coil domain-containing protein 104 (Fragment) 0.77 N N / A 
Q3UHB8 Coiled-coil domain-containing protein 177 0.83 N N / A 
Q52L78 Cryab protein 1.39 Y N 
P19536 Cytochrome c oxidase subunit 5B, mitochondrial  1.37 Y N 
O88485 Cytoplasmic dynein 1 intermediate chain 1  0.80 N N / A 
O35459 Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial 1.19 Y N 
E9Q557 Desmoplakin  1.36 N N / A 
A8QKB4 Destrin (Fragment)  1.26 N N / A 
Q8CDG3 Deubiquitinating protein VCIP135 0.84 N N / A 
A2ALF0 DnaJ homolog subfamily C member 8 0.72 N N / A 
Q3TPZ5 Dynactin 2  0.77 Y N 
Q9Z0Y1 Dynactin subunit 3  1.16 N N / A 
Q3TBU6 Dynamin 2 1.22 N N / A 
P62878 E3 ubiquitin-protein ligase RBX1  0.79 N N / A 
Q99KR6 E3 ubiquitin-protein ligase RNF34  0.81 N N / A 
Q9EQG7 Ectonucleotide pyrophosphatase/phosphodiesterase family member 5 0.76 N N / A 
Q2YDW1 Eif3j protein (Fragment) 0.79 N N / A 
Q99LC5 Electron transfer flavoprotein subunit alpha, mitochondrial 1.23 Y Y 
A2AWI7 Endophilin-B2 1.28 N N / A 
Q3URM4 Endoplasmic Reticulum Protein 44 0.79 N N / A 
P57759 Endoplasmic reticulum resident protein 29 0.79 N N / A 
Q8BH95 Enoyl-CoA hydratase, mitochondrial 1.21 Y Y 
Q5EBJ4 Ermin  1.21 N N / A 
Q9D172 ES1 protein homolog, mitochondrial  1.29 N N / A 
CK054 Ester hydrolase C11orf54 homolog  1.27 N N / A 
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G3UX44 Estradiol 17-beta-dehydrogenase 8 (Fragment) 1.19 N N / A 
Q3TDD8 Eukaryotic Translation Initiation Factor 4B 0.79 N N / A 
P63242 Eukaryotic translation initiation factor 5A-1  0.65 Y Y 
Q9CRS5 EWS RNA-Binding Protein 1 0.78 N N / A 
Q5EBJ0 Fatty acid binding protein 3, muscle and heart  1.47 N N / A 
Q497I3 Fatty acid binding protein 5, epidermal  1.46 N N / A 
P51880 Fatty acid-binding protein, brain  1.27 N N / A 
P26049 Gamma-aminobutyric acid receptor subunit alpha-3 0.77 N N / A 
Q8C3E3 GDP-D-Glucose Phosphorylase 1 0.80 N N / A 
A7VJ98 Glia maturation factor beta  0.65 N N / A 
P03995 Glial fibrillary acidic protein  0.79 Y N 
Q548L6 Glutamate decarboxylase  1.17 Y N 
Q548L4 Glutamate decarboxylase  1.18 N N / A 
F6VNW5 Glutamate--cysteine ligase regulatory subunit (Fragment) 0.75 N N / A 
Q8VD04 GRIP1-associated protein 1 0.82 N N / A 
Q99LP6 GrpE protein homolog 1, mitochondrial  1.23 Y Y 
A2ARF6 GTP:AMP phosphotransferase AK4, mitochondrial (Fragment)  1.27 Y N 
Q3U931 GTPase Activating Protein (SH3 Domain) Binding Protein 2 0.83 N N / A 
Q3UKC8 Guanine nucleotide-binding protein subunit gamma 1.19 N N / A 
Q9R257 Heme-binding protein 1  1.50 N N / A 
Q3TGN5 Heterogeneous Nuclear Ribonucleoprotein U (Scaffold Attachment 
Factor A) 
0.83 N N / A 
P70349 Histidine triad nucleotide-binding protein 1  1.42 N N / A 
A0JLV3 Histone H2B (Fragment)  1.41 N N / A 
E0CZ27 Histone H3 (Fragment)  1.27 N N / A 
Q6B822 Histone H4 (Fragment)  1.37 N N / A 
Q9Z2Y3 Homer protein homolog 1  0.80 N N / A 
Q61249 Immunoglobulin-binding protein 1  0.67 N N / A 
Q9D7P6 Iron-sulfur cluster assembly enzyme ISCU, mitochondrial  1.32 Y Y 
D3YTT4 Isobutyryl-CoA dehydrogenase, mitochondrial  1.21 Y Y 
Q9D6R2 Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial  1.17 Y Y 
Q684I8 Isocitrate dehydrogenase 3 (NAD+), gamma (Fragment)  1.23 Y Y 
Q3TY86 Isoform 2 of Apoptosis-inducing factor 3 0.80 Y N 
Q9D164 Isoform 2 of FXYD domain-containing ion transport regulator 6 0.83 N N / A 
Q68FH0 Isoform 2 of Plakophilin-4 n 1.24 N N / A 
Q62442 Isoform 2 of Vesicle-associated membrane protein 1 1.23 Y N 
Q8R0S4 Isoform 2 of Voltage-dependent L-type calcium channel subunit beta-4 0.84 N N / A 
O88935 Isoform 3 of Synapsin-1 1.20 N N / A 
P09470 Isoform Testis-specific of Angiotensin-converting enzyme 0.77 Y N 
Q9JHI5 Isovaleryl-CoA dehydrogenase, mitochondrial  1.27 Y Y 
Q3TTY6 Lin-7 Homolog C 1.34 N N / A 
B5TVM9 Lisch-like isoform 7 0.81 N N / A 
P70699 Lysosomal alpha-glucosidase  1.19 Y N 
P08249 Malate dehydrogenase, mitochondrial  1.24 Y Y 
Q545I9 MC3T3-E1 calcyclin  1.19 N N / A 
Q5I0U7 MCG122050  1.19 N N / A 
B2RX66 MCG124812  0.77 N N / A 
Q5SQB7 MCG68069  0.77 N N / A 
G3X997 Metallo-beta-lactamase domain-containing protein 2  0.72 N N / A 
Q9EQ20 Methylmalonate-semialdehyde dehydrogenase [acylating], 
mitochondrial 
1.25 Y Y 
P10637 Microtubule-associated protein tau  0.68 Y N 
Q91VR7 Microtubule-associated proteins 1A/1B light chain 3A 1.22 Y N 
G8DXN9 Mitochondrial ATP synthase epsilon subunit (Fragment)  1.30 Y N 
D3YVK5 Mitochondrial import inner membrane translocase subunit Tim10 B 1.35 Y Y 
Q9CQV1 Mitochondrial import inner membrane translocase subunit TIM16  1.30 Y Y 
Q9QYA2 Mitochondrial import receptor subunit T 1.16 Y N 
Q8VEA4 Mitochondrial intermembrane space import and assembly protein 40 1.36 Y Y 
D3YWY6 Mitochondrial pyruvate carrier 1 1.16 Y Y 
Q9JMF0 mRNA, clone:2-63 (Fragment)  0.72 N N / A 
Q3THE2 Myosin regulatory light chain 12B  0.77 N N / A 
Q8K4Z3 NAD(P)H-hydrate epimerase  1.20 Y Y 
Q99LC3 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10, 
mitochondrial 
1.27 Y N 
J. Cell Sci. 129: doi:10.1242/jcs.194241: Supplementary information
Jo
ur
na
l o
f C
el
l S
ci
en
ce
 •
 S
up
pl
em
en
ta
ry
 in
fo
rm
at
io
n
Q9CQ91 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 3  1.25 Y N 
Q9CQZ5 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 6  1.29 Y N 
O09111 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 11, 
mitochondrial  
0.55 Y N 
Q9CQC7 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 4  1.20 Y N 
Q6R891 Neurabin-2  0.77 N N / A 
P06837 Neuromodulin  0.78 N N / A 
Q3U3C2 Niemann-Pick Disease, Type C2 1.16 N N / A 
Q3TV28 Nucleobindin 2 0.74 N N / A 
Q5NC81 Nucleoside diphosphate kinase  1.18 Y Y 
Q9CTE1 Nucleosome Assembly Protein 1-Like 5 1.16 N N / A 
Q8BFY6 Peflin  0.81 N N / A 
Q3TE63 Peptidyl-prolyl cis-trans isomerase  1.43 Y N 
Q99KR7 Peptidyl-prolyl cis-trans isomerase F, mitochondrial  1.33 Y N 
Q3UWS9 Peroxiredoxin 5 1.99 Y N 
B1AXW5 Peroxiredoxin-1 (Fragment) 1.21 Y N 
Q9JJV2 Profilin-2 1.39 N N / A 
Q9DB60 Prostamide/prostaglandin F synthase  1.19 N N / A 
Q5D098 Proteasome subunit beta type (Fragment) 0.82 N N / A 
D6RI64 Protein 1110004F10Rik  0.78 N N / A 
Q9DCM0 Protein ETHE1, mitochondrial 1.23 Y N 
Q8BHZ0 Protein FAM49A 0.75 N N / A 
Q8BUK6 Protein Hook homolog 3 0.84 N N / A 
Q8JZS0 Protein lin-7 homolog A 1.19 N N / A 
Q9D0R8 Protein LSM12 homolog 1.17 N N / A 
H3BKQ7 Protein Ppp1r9a 0.81 N N / A 
Q3UFJ3 Pyruvate dehydrogenase E1 alpha 1 1.21 Y Y 
P34022 Ran-specific GTPase-activating protein 0.78 N N / A 
Q05186 Reticulocalbin-1  1.18 N N / A 
Q5FWK3 Rho GTPase-activating protein 1 1.26 N N / A 
P70122 Ribosome maturation protein SBDS 0.81 N N / A 
Q3URG1 RIKEN cDNA 2900041A09, isoform CRA_a 1.17 Y N 
Q545E6 RNA-binding protein 0.74 N N / A 
G3UXT7 RNA-binding protein FUS (Fragment)  0.80 N N / A 
H3BJI4 RWD domain containing 4A, isoform CRA_b 0.68 N N / A 
Q9JL08 S100 calcium binding protein A1 (Fragment)  0.70 Y Y 
Q545H7 S100 calcium binding protein A13  1.32 N N / A 
Q3ULN6 Saccharopine Dehydrogenase (Putative) 1.16 Y Y 
Q3TT51 Secretogranin V, isoform CRA_b  0.82 N N / A 
D3YWV5 Semaphorin-4A 0.82 N N / A 
B2RUC7 Serine/threonine kinase receptor associated protein 0.81 N N / A 
Q3UEI6 SERPINE1 MRNA Binding Protein 1 0.77 N N / A 
Q3U4F0 Sideroflexin-3  1.16 Y Y 
Q8BJI1 Sodium-dependent neutral amino acid transporter SLC6A17 0.73 N N / A 
Q61609 Sodium-dependent phosphate transporter 1  0.74 N N / A 
Q80UP8 Sodium-dependent phosphate transporter 2  0.69 N N / A 
Q80U52 Sodium/hydrogen exchanger (Fragment)  0.78 Y Y 
D3YYN7 Sodium/potassium-transporting ATPase subunit alpha-2  0.83 N N / A 
Q3UYK6 Solute carrier family 1 (Glial high affinity glutamate transporter), 
member 2 
0.80 N N / A 
Q3US35 Solute Carrier Family 1 (Glutamate/Neutral Amino Acid Transporter), 
Member 4 
0.77 N N / A 
Q67BT3 Solute carrier family 13 member 5 0.74 N N / A 
Q8BPS5 Solute Carrier Family 16 (Monocarboxylate Transporter), Member 1 0.77 Y Y 
P17809 Solute carrier family 2, facilitated glucose transporter member 1 0.53 Y Y 
Q9CX10 Solute Carrier Family 25, Member 27 1.24 Y Y 
Q14C53 Solute carrier family 39 (Zinc transporter), member 7 0.63 N N / A 
Q62417 Sorbin and SH3 domain-containing protein 1 0.81 N N / A 
D3Z789 Sorting nexin-3 1.31 N N / A 
Q9Z2I9 Succinyl-CoA ligase [ADP-forming] subunit beta, mitochondrial 1.21 Y Y 
Q9WUM5 Succinyl-CoA ligase [ADP/GDP-forming] subunit alpha, mitochondrial  1.18 Y Y 
Q3UK61 Succinyl-CoA:3-ketoacid-coenzyme A transferase  1.22 Y Y 
Q3U8W4 Superoxide dismutase  1.22 Y N 
P08228 Superoxide dismutase [Cu-Zn]  1.28 Y N 
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Q64332 Synapsin-2 1.23 N N / A 
Q9ERB0 Synaptosomal-associated protein 29 0.76 N N / A 
I3PMU3 Syndecan (Fragment)  0.57 N N / A 
P70452 Syntaxin-4  0.78 N N / A 
Q3UKC1 Tax1-binding protein 1 homolog 0.76 N N / A 
P97930 Thymidylate kinase 1.16 Y Y 
A2AEC2 Transcription elongation factor A protein-like 3 (Fragment) 0.75 N N / A 
P62869 Transcription elongation factor B polypeptide 2  1.23 N N / A 
Q8VDE3 Translation elongation factor (Fragment)  1.17 Y Y 
Q8CHW4 Translation initiation factor eIF-2B subunit epsilon 0.76 N N / A 
P63028 Translationally-controlled tumor protein 0.80 Y N 
Q9JKK7 Tropomodulin-2  0.72 N N / A 
O54818 Tumor protein D53  1.18 N N / A 
P24529 Tyrosine 3-monooxygenase  1.16 Y N 
Q3T992 Ubiquilin 1 1.25 N N / A 
A2RTT4 Ubiquitin-Conjugating Enzyme E2N 1.29 N N / A 
O08759 Ubiquitin-protein ligase E3A  0.80 N N / A 
F2Z452 Uncharacterized protein  0.75 N N / A 
Q8VE95 UPF0598 protein C8orf82 homolog  1.40 N N / A 
Q99KC8 von Willebrand factor A domain-containing protein 5A 0.77 N N / A 
E0CYH4 WD repeat-containing protein 26  0.82 N N / A 
D3Z7N4 Zinc transporter ZIP6 (Fragment)  0.65 N N / A 
UniProt: Uniprot Accession; Description: Protein description; Ratio: Ratio between the expression levels of a given protein in α-syn-/- mice 
compared to α-syn+/+. Average of two technical replicas; Mitochondria Evidence: N: No. Y: Yes. Evidence that a given protein is localised 
in mitochondria; or that it influences or is influenced by mitochondrial function; Novel N: No; Y: Yes; N/A: Not Applicable. Evidence that 
a given protein has previously been associated with α-synuclein, Parkinson's Disease or Neurodegeneration in general. 
Table S2: Buffer compositions. 
Buffer Compound Concentration 
iTRAQ buffer Urea 6 M 
Thio-urea 2M 
CHAPS 2% 
SDS 0.5% 
Protease Inhibitors 1% 
Isolation Media Sucrose 225 mM 
pH 7.4 Mannitol 75 mM 
EGTA 1 mM 
HEPES 5 mM 
Incubation Media NaCl 120 mM 
37°C KCl 3.5 mM 
CaCl2 1.3 mM 
KH2PO4 0.4 mM 
Na2SO4 1.2 mM 
MgSO4 2 mM 
Glucose 15 mM 
Pyruvate 10 mM 
Fatty-acid free BSA 4 mg/mL 
J. Cell Sci. 129: doi:10.1242/jcs.194241: Supplementary information
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Table S3: Antibodies used for Western Blotting. 
Antibody Catalog No Supplier Concentration 
α-synuclein sc-7011-R santa cruz biotechnology 1:5000 
β-actin ab8226 abcam 1:5000 
ATP5A ab176569 abcam 1:5000 
COX IV ab14744 abcam 1:1000 
GAPDH ab9484 abcam 1:1000 
NDUFB8 MS105 Mitosciences 1:1000 
sfxn3 HPA008028 Sigma Aldrich 1:400 
VDAC 2 ab47104 abcam 1:500 
IRDye® 800CW Donkey anti-
Mouse IgG (H + L) 
926-32212 LiCOR Biosciences 1:5000 
IRDye® 680RD Donkey anti-
Rabbit IgG (H + L) 
926-68073 LiCOR Biosciences 1:5000 
For use with anti-α-synuclein antibodies, the membranes were fixed in 0.4% PFA in PBS for 20 min and washed 
in PBS prior to blocking, as this method has been shown to increase the sensitivity of α-synuclein detection (Lee 
and Kamitani, 2011). 
Figure S1: Graphical representation of the filtering steps taken during the analysis of iTRAQ proteomics 
data. Y-axis represents the mean fold change, from two technical replicates, of each protein in α-syn-/-
synaptosomes when compared to control α-syn+/+ synaptosomes. “Unfiltered” column includes all 2,615 proteins 
identified by iTRAQ. “Filtered” column contains the subset of identified protein which met the selection criteria 
of being identified by more than 1 unique peptide and being altered by more than 15% in two technical replicates. 
Since mitochondrial pathways were shown to be some of the most affected in α-syn-/- mice (Table 1), the 200 
filtered proteins were further selected to include only mitochondrial proteins (“Mitochondrial” column, 74 
proteins). Mitochondrial proteins were further filtered to include proteins not previously associated with α-
synuclein or neurodegeneration (see methods). These group of 37 proteins, here referred to as “novel 
J. Cell Sci. 129: doi:10.1242/jcs.194241: Supplementary information
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mitochondrial”, was prioritized for a literature search on subtle links to synaptic stability and neurodegenerative 
processes.  
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